NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Jefferies Reiterates Buy Rating on Amgen (AMGN) as Lumakras Phase III CB200 Hits

August 31, 2022 8:29 AM EDT

Jefferies analyst Michael Yee reiterated a Buy rating and $295.00 price target on Amgen (NASDAQ: AMGN) after Lumakras Phase III CB200 hits, which he said is "good enough."

The analyst commented, "AMGN announced the Lumakras Phase III CB-200 study was positive although mostly... More